Biologics Inc., which is owned by McKesson Specialty Health, has been chosen as the exclusive specialty pharmacy provider for BAVENCIO (avelumab).
A pharmacy services company which an oncology focus, the decision to have Biologics be the provider for BAVENCIO was made by EMD Serono. Biologics has a large team of specialists offering top care for patients and boasting personalized health care for individuals. Made up of a pharmacist, oncology nurse and financial counselor, Biologics is well-suited to provide expertise over a number of categories associated with pharmaceutical aid.
BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody. It is anticipated to be an effective treatment for adults and patients 12 years of age and older who are battling metastatic Merkel cell carcinoma.
The breakthrough medication offers hope for individuals who prior had a bleak outlook, with less than 20 percent of patients surviving for over five years.
In its international Phase II trial, BAVENCIO showed that 78.6 percent of patients responded to the medication in seven weeks' time, with the undesirable side effects being listed as fatigue and infusion complications.
"We are honored to be chosen as the exclusive specialty pharmacy provider for BAVENCIO and are prepared to support the clinical, financial and emotional needs of this patient population," Biopharma Services Vice President Brandon Tom said.
Alerts Sign-up